Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer

被引：15
|
作者：
Ban, Marija [1 ]
Mise, Branka Petric [1 ]
Majic, Ana [1 ]
Drazic, Ivanka [1 ]
Vrdoljak, Eduard [1 ]
机构：
[1] Univ Hosp Ctr Split, Split Sch Med, Dept Oncol & Radiotherapy, Spinciceva 1, Split 21000, Croatia
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 06期
关键词：
breast; cancer; heavily pretreated; HER2-; hormone receptor positive; metastatic; palbociclib; EVEROLIMUS PLUS EXEMESTANE; 4/6 INHIBITOR PALBOCICLIB; ENDOCRINE RESISTANCE; GROWTH-FACTOR; PHASE-II; ABEMACICLIB; COMBINATION; EXPRESSION; LETROZOLE;
D O I：
10.2217/fon-2017-0491
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: CDK4/6 inhibitors in the first and second treatment line in patients with HR+/HER2-metastatic breast cancer (mBC) in combination with hormonal therapy improve progression-free survival. Role of CDK4/6 inhibitors in further treatment lines remains unclear. Methods: Retrospective analysis of 24 HR+/HER2- heavily pretreated mBC patients is presented. Results: A total of 58.3% patients achieved stable disease. No objective response was observed. Median progression-free survival was 4.8 months; median overall survival was 11 months. Treatment was well tolerated. Conclusion: Favorable toxicity profile and efficacy of palbociclib/aromatase inhibitors combination in heavily pretreated luminal mBC patients in this study emphasize the need for further investigation of such drugs in this population.
引用
收藏
页码：537 / 544
页数：8
相关论文
共 50 条
  • [31] Economic Burden of HR+/HER2-Metastatic Breast Cancer Among Adult Premenopausal Women
    Gauthier, Genevieve
    Gagnon-Sanschagrin, Patrick
    Guerin, Annie
    Burne, Rebecca
    Small, Tania
    Niravath, Polly
    Dalal, Anand A.
    [J]. ADVANCES IN THERAPY, 2018, 35 (04) : 503 - 514
  • [32] Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2-metastatic breast cancer
    Goyal, R. K.
    Carter, G. C.
    Nagar, S. N.
    Smyth, E. N.
    Price, G. L.
    Huang, Y-J
    Bromund, J. L.
    Li, L.
    Schilder, J. M.
    Davis, K. L.
    Kaye, J. A.
    [J]. CANCER RESEARCH, 2017, 77
  • [33] Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2-metastatic breast cancer administered abemaciclib plus pembrolizumab.
    Tolaney, Sara M.
    Kabos, Peter
    Dickler, Maura N.
    Gianni, Luca
    Jansen, Valerie
    Lu, Yi
    Young, Suzanne
    Rugo, Hope S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Osako, Tomo
    Ito, Yoshinori
    Takahashi, Shunji
    Tokudome, Nahomi
    Iwase, Takuji
    Hatake, Kiyohiko
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (01) : 159 - 164
  • [35] Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Tomo Osako
    Yoshinori Ito
    Shunji Takahashi
    Nahomi Tokudome
    Takuji Iwase
    Kiyohiko Hatake
    [J]. Cancer Chemotherapy and Pharmacology, 2008, 62 : 159 - 164
  • [36] Real-world evidence of efficacy and activity of palbociclib plus endocrine therapy and post-progression treatments in HR+/HER2-metastatic breast cancer patients: The PALPract study
    Fabi, Alessandra
    Russillo, Michelangelo
    Ciccarese, Mariangela
    Scagnoli, Simone
    Schettini, Francesco
    Buono, Giuseppe
    Lo Russo, Vito
    Arpino, Grazia
    Rossella, Rosalba
    Sarobba, Giuseppina
    Giampaglia, Marianna
    Pellegrini, Patrizia
    Stani, Simonetta
    Palleschi, Michela
    Adamo, Vincenzo
    Morelli, Francesca
    Fabbri, Maria Agnese
    Nistico, Cecilia
    Ferretti, Gianluigi
    Catania, Giovanna
    Pisegna, Simona
    Giannarelli, Diana
    Cognetti, Francesco
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [37] Exploring pharmacokinetic variability of palbociclib in HR+/HER2-metastatic breast cancer: a focus on age, renal function, and drug-gene interactions
    Peruzzi, Elena
    Posocco, Bianca
    Gerratana, Lorenzo
    Nuti, Margherita
    Orleni, Marco
    Gagno, Sara
    De Mattia, Elena
    Puglisi, Fabio
    Cecchin, Erika
    Toffoli, Giuseppe
    Roncato, Rossana
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [38] Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2-Metastatic Breast Cancer
    Jeselsohn, Rinath
    Fu, Jingxin
    Ren, Yue
    Mahtani, Reshma
    Ma, Cynthia
    DeMichele, Angela
    Cristofanilli, Massimo
    Meisel, Jane
    Miller, Kathy
    Abdou, Yara
    Riley, Elizabeth
    Qamar, Rubina
    Sharma, Priyanka
    Reid, Sonya
    Ko, Naomi
    Liu, Yuan
    Burstein, Harold
    DeMeo, Michelle
    Tolaney, Sara
    Mayer, Erica
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [39] PALBOSPAIN: OBSERVATIONAL ANALYSIS OF FIRST-LINE THERAPY WITH PALBOCICLIB IN PATIENTS WITH HR+/HER2-METASTATIC BREAST CANCER (MBC) IN REAL-LIFE CONDITIONS
    Martinez-Janez, Noelia
    Ezquerra, Meritxell Bellet
    Henao, Fernando
    Manso, Luis
    Anton, Antonio
    Zamora, Pilar
    Murillo, Serafin Morales
    Tolosa, Pablo
    Andres, Raquel
    Calvo, Lourdes
    Galve, Elena
    Lopez, Rafael
    de la Pena, Francisco Ayala
    Lopez-Tarruella, Sara
    Boronat, Laia
    Martos, Tamara
    Chacon, J. Ignacio
    Alvarez, Isabel
    de la Haba-Rodriguez, Juan
    Anton, Fernando Moreno
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [40] Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer
    Ates, Ozturk
    Babacan, Taner
    Kertmen, Neyran
    Sarici, Furkan
    Cenoli, Alma
    Akin, Serkan
    Karakas, Yusuf
    Kilickap, Saadettin
    Ozisik, Yavuz
    Sever, Ali R.
    Aksoy, Sercan
    Altundag, Kadri
    [J]. JOURNAL OF BUON, 2016, 21 (02): : 375 - 381
12345